February 25, 2015 12:57 PM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Bristol-Myers Squibb Co. (NYSE: BMY) launched a Phase III trial of an experimental HIV treatment for patients who have become resistant to other therapies.Shares of the New York-based pharmaceuticals giant changed hands recently at $61.27, down $0.18 cents.Positive interim results of an ongoing Phase IIb safety trial enabled launch of the Phase III clinical trial on Monday, Bristol-Myers said.After 48 weeks, the safety trial didn't result in serious adverse events or safety concerns related to dose responses.Results of the safety trial were presented Tuesday at a Seattle conference on retroviruses and opportunistic infections.The clinical development program for the drug, Fostemsavir, or BMS-663068, "exemplifies our commitment to focusing on patients living with HIV who have high unmet needs," according to Douglas Manion, head of specialty development, Bristol-Myers Squibb.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.